Anderson Karen M.

Chief People Officer Karen M. Anderson sold 41,076 shares of CNTA at $30.12 (total $1.2M), reducing stake 39.8% to 62,085 shares.

Anderson sold 41,076 shares at $30.12 on 2026-03-26, the fourth sale within a 10-day span (prior sales on 2026-03-17, 2026-03-16, and twice on 2026-03-13). This concentrated selling activity at prices near the 52-week high of $29.91 represents a substantial reduction in her holdings (from 103,161 to 62,085 shares, a -39.8% decrease). Her cross-ticker track record shows 8 prior sells with a 100.00% well-timed rate at the 90-day mark (average 90d return -29.4%), and at CNTA specifically, her sole measurable historical sale on 2025-02-10 posted -35.2% 90-day return. Centessa faces significant operational headwinds: the company reported $0.00 latest-quarter revenue, a net loss of $-54,891,000.00, and -100.0% annual revenue growth, with a $3.9B market cap despite ongoing unprofitability. The rapid succession of sales by the Chief People Officer amid deteriorating fundamentals and at elevated valuations warrants investor attention.

Chief People Officer Karen M. Anderson sold 74,811 shares (54.6% of holdings) at $28.19 avg on 2026-03-16/17 ($2.1M)

Anderson executed 2 separate sales totaling 74,811 shares for $2,109,179.58 on March 16–17, reducing her stake from 136,896 shares to 62,085 shares—a 54.6% reduction in holdings. Her cross-ticker track record shows 6 prior sells with a 100.00% well-timed rate at the 90-day mark, and at CNTA specifically, all 3 prior measurable sales (2025-02-10, 2025-02-07, 2024-03-25) were well-timed, with 90-day declines ranging from -21.9% to -35.2%. Against this backdrop, the magnitude of this divestment (nearly 75K shares) by the Chief People Officer is notable. The company is unprofitable with $-54,891,000.00 net income and -100.0% annual revenue growth, creating a fundamental backdrop where pattern-consistent insider selling warrants investor attention—particularly given the concentration and speed of this reduction relative to her prior activity.

CPO Karen M. Anderson sold 120,029 shares (120.0K) at blended average $26.25 for $3,150,672.76 (-65.9% of holdings)

Anderson Karen M., Chief People Officer, executed 2 separate sales totaling 120,029 shares for $3,150,672.76, reducing her holdings by -65.9% from 182,114 shares to 62,085 shares. Her prior 4 sales at CNTA all posted negative 90-day returns (ranging -21.9% to -35.2%), establishing a consistent pattern where the stock subsequently declined after her sales. Against current company fundamentals (Revenue $0.00 latest quarter, Net income $-54,891,000.00, Annual revenue growth -100.0%), this substantial divestiture represents a material reduction in her stake at an unprofitable biotech. The timing and scale of this sale, coupled with her prior well-timed exit pattern at this ticker (4 of 4 prior sells negative at 90 days), warrant close monitoring of the company's near-term trajectory and insider confidence indicators.

Chief People Officer Karen M. Anderson sold 30,955 shares for $588,943.54; -36.3% of holdings. Prior CNTA sales both well-timed at 90d mark.

Anderson Karen M., Chief People Officer, executed 2 separate sales totaling 30,955 shares for $588,943.54, reducing her holdings from 85,277 to 54,322 shares (-36.3% of pre-transaction holdings). The sales occurred at an average price of $19.03, near the 52-week high of $19.03, compared to a current price of $17.79. Her prior 2 sales at CNTA in March 2024 were both well-timed at the 90-day mark, with negative returns of -18.8% and -22.5% respectively, suggesting a pattern of selling ahead of declines at this ticker. The company remains unprofitable with net income of $-42,566,000.00, providing context for elevated scrutiny of insider liquidity decisions. The timing of this sale at peak price levels, paired with the insider's demonstrated pattern of well-timed sales at this specific ticker, warrants monitoring of subsequent price action.